康希诺(06185.HK)急涨9.6%成交创近期新高 正联合开发重组新冠病毒疫苗
康希诺生物(06185.HK)正在联合开发重组新冠病毒疫苗,该股回落守稳50天线,今天股价高见96.2元,暂受制本月初所创上市高位98元,现造85.7元,急涨9.6%,成交急增至440万股,为近期最多,涉资3.76亿元。
康希诺公布,与军事科学院军事医学研究院生物工程研究所正在联合开发重组新型冠状病毒疫苗(腺病毒载体)(「Ad5-nCoV」),该疫苗采用基因工程方法构建,以复制缺陷型人5型腺病毒为载体,可表达新型冠状病毒S抗原,拟用於预防新型冠状病毒感染引起的疾病。联合开发方已向监管机构提出Ad5-nCoV的新药临床试验预审评申请,目前正在按照要求滚动提交後续技术资料,以及开始临床试验准备工作和受试者预招募工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.